| Jason Michael Baker, MD | |
|
10670 Ne Cornell Rd Ste 300, Hillsboro, OR 97124-9221 | |
| (503) 216-9300 | |
| Not Available |
| Full Name | Jason Michael Baker |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 10670 Ne Cornell Rd Ste 300, Hillsboro, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154702538 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD189444 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Home Health | Portland, OR | Home health agency |
| Providence Hospice | Portland, OR | Hospice |
| Providence St Vincent Medical Center | Portland, OR | Hospital |
| Providence Portland Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
| Providence Health And Services Oregon | 9335057447 | 125 |
News Archive
People who have their stomach size surgically reduced move around more and easier after weight loss surgery, a study has found.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.
NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Johns Hopkins scientists have developed a potentially novel way to fight colorectal cancer using tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike current treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects.
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
People who have their stomach size surgically reduced move around more and easier after weight loss surgery, a study has found.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.
NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Johns Hopkins scientists have developed a potentially novel way to fight colorectal cancer using tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike current treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects.
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114015971 PECOS PAC ID: 9335057447 Enrollment ID: O20031117000153 |
News Archive
People who have their stomach size surgically reduced move around more and easier after weight loss surgery, a study has found.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.
NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Johns Hopkins scientists have developed a potentially novel way to fight colorectal cancer using tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike current treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects.
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
People who have their stomach size surgically reduced move around more and easier after weight loss surgery, a study has found.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.
NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Johns Hopkins scientists have developed a potentially novel way to fight colorectal cancer using tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike current treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Michael Baker, MD Po Box 3158, Portland, OR 97208-3158 Ph: (503) 215-6494 | Jason Michael Baker, MD 10670 Ne Cornell Rd Ste 300, Hillsboro, OR 97124-9221 Ph: (503) 216-9300 |
News Archive
People who have their stomach size surgically reduced move around more and easier after weight loss surgery, a study has found.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.
NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Johns Hopkins scientists have developed a potentially novel way to fight colorectal cancer using tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike current treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects.
› Verified 9 days ago
Karla Carolina Acosta, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10060 Ne Evergreen Pkwy, Hillsboro, OR 97124 Phone: 503-813-2000 | |
Andrew G Janssen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7529 Se Tualatin Valley Hwy, Hillsboro, OR 97123 Phone: 503-681-4369 | |
Dr. Derrick Eugene Custino, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 19400 Nw Evergreen Pkwy, Hillsboro, OR 97124 Phone: 503-645-2762 Fax: 503-690-5023 | |
Michael Powel Hicken, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5295 Ne Elam Young Pkwy, Suite 180, Hillsboro, OR 97124 Phone: 503-615-0960 Fax: 503-615-8572 | |
Dr. Judith Marie Kemp, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6244 Ne Brighton St, Hillsboro, OR 97124 Phone: 503-615-3100 Fax: 503-615-8572 | |
Van Anh T Nguyen, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 265 Se Oak St, Hillsboro, OR 97123 Phone: 503-216-0850 | |
Ann G. Tseng, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10690 Ne Cornell Rd Ste 220, Hillsboro, OR 97124 Phone: 503-848-5861 |